GLP-1 Medications and Hip Arthritis: What We Know, and What We're Extrapolating
Can Ozempic, Wegovy, Mounjaro or Zepbound help hip arthritis or delay a hip replacement? What the hip-specific research shows, and what is borrowed from the knee.
A patient in her early sixties came to see me recently with a painful hip and a new prescription for a GLP-1 medication. Her first question wasn't about surgery. It was, "If I lose the weight, will my hip get better? Might I avoid the replacement?" I hear some version of that every week now.
Here is the honest answer. Most of what has been published on GLP-1 drugs (semaglutide and tirzepatide, sold as Ozempic, Wegovy, Mounjaro and Zepbound) and arthritis is about the knee. The hip data is thinner. There are encouraging signals, but nothing that proves these drugs slow hip arthritis. Below I separate what is hip-specific from what is borrowed from the knee.
What the hip data actually show
The largest hip-specific look comes from a retrospective study of a national health-record database1. Researchers matched patients with a BMI of 30 or higher who already had hip arthritis, comparing those who took a GLP-1 medication with those who did not. There were 6,714 matched pairs, followed for one year.
In plain terms, people on a GLP-1 drug were about half as likely to go on to hip replacement in that first year. That is a real signal. But "associated with fewer replacements" is not the same as "slows hip arthritis," and the difference matters.
Why I'm not ready to call it disease-modifying
Three things keep me cautious. First, this was a retrospective database study. It cannot tell us about dose, whether patients actually took the medication, or why some people chose to put surgery off. A patient who is feeling better on a new medication, or who is simply waiting to lose more weight before surgery, looks the same in the data as a patient whose joint is truly doing better.
Second, the BMI change in the hip arthritis group was small and nearly the same in both groups (about 0.9 versus 1.0 points)1. The authors point to that as a hint that something other than weight loss may be going on, and animal and cell studies suggest semaglutide may act on joint tissue directly. That is interesting, but it is lab work, and it needs to be confirmed in people.
Third, the same study found something that does not fit the story. Among patients who did not have arthritis at the start, GLP-1 users were diagnosed with new hip arthritis slightly more often (0.9% versus 0.7%)1. The authors consider this unexpected and think unmeasured factors, like changes in activity or more medical visits, could explain it. I would rather tell you about it than leave it out.
Hip-specific versus borrowed from the knee
| Question | Hip evidence | Knee evidence | How firm |
|---|---|---|---|
| Fewer replacements at one year | 1.1% vs 2.2% (HR 0.60) | 1.4% vs 2.1% (HR 0.75) | Observational only |
| Is it just weight loss? | BMI change similar in both groups | Not settled | Unproven |
| Direct effect on cartilage | Not shown in people | Animal and cell studies | Preclinical |
| Results after hip replacement | Lower 90-day readmission and early revision in pooled cohorts | Similar signals reported | Very low certainty |
If you are on a GLP-1 and need a hip replacement
A pooled analysis of six retrospective U.S. cohorts looked at patients having a primary hip replacement: 11,869 GLP-1 users and 22,777 comparison patients2. GLP-1 users had a lower 90-day readmission rate (odds ratio 0.81) and a lower rate of early revision surgery (odds ratio 0.70). There was no difference in infection, blood clots or long-term revision. The authors rated the certainty of the evidence as very low, and there are no randomized trials. I read that as reassuring, not as a reason to start a drug in hopes of a better surgery.
One practical point: tell your surgical team and anesthesia team that you are on one of these medications well before surgery. Instructions about timing of doses are evolving, and they are best settled with the people doing your anesthesia.
Who I talk to about this
I talk through GLP-1 medications with patients who have hip or knee arthritis and a higher BMI, whether they are already on one or thinking about it. For them, losing weight is a reasonable goal on its own terms, because it takes load off the joint and tends to make surgery safer. I also see patients who are already planning a hip replacement and want to know how the medication fits in. And I see patients who are hoping a drug will let them skip surgery entirely. For those patients I am direct: these medications may help symptoms and overall health, but they will not regrow cartilage or fix a hip that is bone-on-bone.
Frequently asked questions
Will a GLP-1 medication keep me from needing a hip replacement?
We do not know. Users had fewer replacements in one study, but that does not show the drug changed the joint. If your hip is severely worn, weight loss alone is unlikely to remove the need for surgery.
Should I start a GLP-1 just for my hip?
I would not start one only for that reason. These are prescription drugs with their own risks and costs. If you and your primary care doctor are already considering one for weight or diabetes, your hip is one more potential benefit.
Does being on a GLP-1 change my hip replacement?
Tell us early. Beyond the anesthesia considerations, early data suggest outcomes are at least as good, but the evidence is low certainty.
If you are weighing a GLP-1 medication or hip surgery, bring your questions to clinic. We can look at your imaging, talk through where your hip actually stands, and decide on the next step together.
References
- Porto JR, Lavu MS, Hecht CJ, Kaelber DC, Sculco PK, Heckmann ND, Kamath AF. The impact of contemporary glucagon-like peptide-1 receptor agonists on the onset, severity, and conversion to arthroplasty in hip and knee osteoarthritis. Orthop J Sports Med. 2025;13(1). doi:10.1177/23259671241297157
- Zaffar H, Imran MA, Hussain S, Rushd F. Impact of glucagon-like peptide-1 receptor agonists on hip arthroplasty outcomes: a systematic review and meta-analysis. Cureus. 2025;17(11):e96279. doi:10.7759/cureus.96279. PMID 41362522
This article is general education, not medical advice for your situation. Every knee and hip is different — talk with your own doctor about your care.